Skip to content
Sign in
Mr. Shkreli (cropped)House Committee on Oversight and Government Reform · Public domain
DevelopingHealthReported 2026-10-13 20:00

FTC and States Seek Contempt for Martin Shkreli’s Alleged Violations of Pharmaceutical Industry Ban

The FTC and seven states have asked a federal court to hold Martin Shkreli in contempt for allegedly violating a 2022 court order that banned him from the pharmaceutical industry, including by trading in pharmaceutical stocks and commenting on industry companies.

In depthRead the in-depth story

Why it matters. The case highlights ongoing enforcement efforts against anticompetitive practices in the pharmaceutical industry and the potential for significant penalties for non-compliance.

01

Who and what it touches

2022 court order bann…regulated by2022 permanent injunc…regulated by2022 civil court orde…regulated byCourt-ordered lifetim…regulated byMartin Shkreli

From Martin Shkreli

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • FFTC NewsRegulator2026-10-13 20:00
    The joint motion alleges numerous examples of Shkreli violating the order’s lifetime ban by publicly trading in pharmaceutical industry stocks of at least 60 companies
    View source
  • CCNBC top newsMedia2026-10-13 21:39
    View source
  • TThe Guardian worldMedia2026-10-14 00:54
    View source